Skip to main content
Top

Open Access 23-01-2025 | Parkinson Disease | Neurology and Preclinical Neurological Studies - Review Article

Impact of diabetes mellitus type two on incidence and progression of Parkinson’s disease: a systematic review of longitudinal patient cohorts

Authors: Olga Stockmann, Lan Ye, Stephan Greten, David Chemodanow, Florian Wegner, Martin Klietz

Published in: Journal of Neural Transmission

Login to get access

Abstract

Parkinson’s disease (PD) is a chronic neurodegenerative disease of the elderly. Patients suffer from progressive motor and non-motor symptoms. Further, PD patients often present geriatric features like multimorbidity and polypharmacotherapy. A frequent comorbidity of PD patients is diabetes mellitus type two (T2DM). In the last decade growing evidence emerged on the impact of T2DM on PD. Of the present review was to analyze the impact of T2DM on PD incidence and progression in patient cohorts. A systematic review of the literature was performed via PubMed and Google Scholar. Studies on longitudinal PD patient cohorts with at least 10 patients per group were included. The diabetic state of the patient had to be determined. In total, 15 studies were analyzed for this review. According to most of the included studies T2DM increases the risk of developing PD significantly. Disease progression is augmented by T2DM both for motor and cognitive impairments. Some studies also point out a correlation of motor worsening and diabetic status measured by the serum HbA1c level. In relation to biomarkers, PD patients with diabetes have higher neurofilament light chain and Tau level but lower Amyloid beta level. T2DM seems to be a risk factor for the development and progression of PD. PD patients should be screened for T2DM and treatment should be initiated promptly. There is still a lack of knowledge about the molecular mechanisms leading to interactions of these diseases.
Literature
go back to reference Aguirre-Vidal Y, Montes S, Mota-López AC, Navarrete-Vázquez G (2024) Antidiabetic drugs in Parkinson’s disease. Clin Park Relat Disord 11:100265PubMedPubMedCentral Aguirre-Vidal Y, Montes S, Mota-López AC, Navarrete-Vázquez G (2024) Antidiabetic drugs in Parkinson’s disease. Clin Park Relat Disord 11:100265PubMedPubMedCentral
go back to reference Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675CrossRefPubMedPubMedCentral Athauda D, Maclagan K, Skene SS et al (2017) Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet 390:1664–1675CrossRefPubMedPubMedCentral
go back to reference Bohnen NI, Kotagal V, Müller MLTM et al (2014) Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord 20:1394–1398CrossRefPubMedPubMedCentral Bohnen NI, Kotagal V, Müller MLTM et al (2014) Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease. Parkinsonism Relat Disord 20:1394–1398CrossRefPubMedPubMedCentral
go back to reference Brauer R, Wei L, Ma T et al (2020) Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes. Brain 143:3067–3076CrossRefPubMedPubMedCentral Brauer R, Wei L, Ma T et al (2020) Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes. Brain 143:3067–3076CrossRefPubMedPubMedCentral
go back to reference Cereda E, Barichella M, Cassani E et al (2012) Clinical features of Parkinson disease when onset of diabetes came first: A case-control study. Neurology 78:1507–1511CrossRefPubMed Cereda E, Barichella M, Cassani E et al (2012) Clinical features of Parkinson disease when onset of diabetes came first: A case-control study. Neurology 78:1507–1511CrossRefPubMed
go back to reference De Pablo-Fernandez E, Goldacre R, Pakpoor J et al (2018) Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology 91:e139–e142CrossRefPubMed De Pablo-Fernandez E, Goldacre R, Pakpoor J et al (2018) Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study. Neurology 91:e139–e142CrossRefPubMed
go back to reference Deng Y, Zhang Y, Li Y et al (2012) Occurrence and distribution of salsolinol-like compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains. J Neural Transm 119:435–441CrossRefPubMed Deng Y, Zhang Y, Li Y et al (2012) Occurrence and distribution of salsolinol-like compound, 1-acetyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (ADTIQ) in parkinsonian brains. J Neural Transm 119:435–441CrossRefPubMed
go back to reference Denroche HC, Verchere CB (2018) IAPP and type 1 diabetes: implications for immunity, metabolism and islet transplants. J Mol Endocrinol 60:R57–R75CrossRefPubMed Denroche HC, Verchere CB (2018) IAPP and type 1 diabetes: implications for immunity, metabolism and islet transplants. J Mol Endocrinol 60:R57–R75CrossRefPubMed
go back to reference Eizirik DL, Pasquali L, Cnop M (2020) Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol 16:349–362CrossRefPubMed Eizirik DL, Pasquali L, Cnop M (2020) Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Rev Endocrinol 16:349–362CrossRefPubMed
go back to reference Geng C, Meng K, Zhao B et al (2024) Causal relationships between type 1 diabetes mellitus and Alzheimer’s disease and Parkinson’s disease: a bidirectional two-sample Mendelian randomization study. Eur J Med Res 29:53CrossRefPubMedPubMedCentral Geng C, Meng K, Zhao B et al (2024) Causal relationships between type 1 diabetes mellitus and Alzheimer’s disease and Parkinson’s disease: a bidirectional two-sample Mendelian randomization study. Eur J Med Res 29:53CrossRefPubMedPubMedCentral
go back to reference Gialluisi A, De Bartolo MI, Costanzo S et al (2023) Risk and protective factors in Parkinson’s disease: a simultaneous and prospective study with classical statistical and novel machine learning models. J Neurol 270:4487–4497CrossRefPubMed Gialluisi A, De Bartolo MI, Costanzo S et al (2023) Risk and protective factors in Parkinson’s disease: a simultaneous and prospective study with classical statistical and novel machine learning models. J Neurol 270:4487–4497CrossRefPubMed
go back to reference Greten S, Müller-Funogea JI, Wegner F et al (2021) Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. J Neural Transm (Vienna) 128:49–60CrossRefPubMed Greten S, Müller-Funogea JI, Wegner F et al (2021) Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis. J Neural Transm (Vienna) 128:49–60CrossRefPubMed
go back to reference Horvath I, Wittung-Stafshede P (2016) Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson’s disease. Proc Natl Acad Sci U S A 113:12473–12477CrossRefPubMedPubMedCentral Horvath I, Wittung-Stafshede P (2016) Cross-talk between amyloidogenic proteins in type-2 diabetes and Parkinson’s disease. Proc Natl Acad Sci U S A 113:12473–12477CrossRefPubMedPubMedCentral
go back to reference Hu G, Jousilahti P, Bidel S et al (2007) Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care 30:842–847CrossRefPubMed Hu G, Jousilahti P, Bidel S et al (2007) Type 2 diabetes and the risk of Parkinson’s disease. Diabetes Care 30:842–847CrossRefPubMed
go back to reference Kleinridders A, Cai W, Cappellucci L et al (2015) Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci U S A 112:3463–3468CrossRefPubMedPubMedCentral Kleinridders A, Cai W, Cappellucci L et al (2015) Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci U S A 112:3463–3468CrossRefPubMedPubMedCentral
go back to reference Klietz M, Greten S, Wegner F, Höglinger GU (2019) Safety and tolerability of pharmacotherapies for Parkinson’s disease in geriatric patients. Drugs Aging 36:511–530CrossRefPubMed Klietz M, Greten S, Wegner F, Höglinger GU (2019) Safety and tolerability of pharmacotherapies for Parkinson’s disease in geriatric patients. Drugs Aging 36:511–530CrossRefPubMed
go back to reference Kopp KO, Glotfelty EJ, Li Y, Greig NH (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res 186:106550CrossRefPubMedPubMedCentral Kopp KO, Glotfelty EJ, Li Y, Greig NH (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res 186:106550CrossRefPubMedPubMedCentral
go back to reference Kotagal V, Albin RL, Müller MLTM et al (2013) Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 19:522–526CrossRefPubMedPubMedCentral Kotagal V, Albin RL, Müller MLTM et al (2013) Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism Relat Disord 19:522–526CrossRefPubMedPubMedCentral
go back to reference Lv Y-Q, Yuan L, Sun Y et al (2022) Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model. Transl Neurodegener 11:14CrossRefPubMedPubMedCentral Lv Y-Q, Yuan L, Sun Y et al (2022) Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model. Transl Neurodegener 11:14CrossRefPubMedPubMedCentral
go back to reference Malatt C, Wu T, Bresee C et al (2022) Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease: A Randomized, Double-Blind, Placebo-Controlled Trial (P9–11.005). Neurology 98(18_Supplement):3068CrossRef Malatt C, Wu T, Bresee C et al (2022) Liraglutide Improves Non-Motor Function and Activities of Daily Living in Patients with Parkinson’s disease: A Randomized, Double-Blind, Placebo-Controlled Trial (P9–11.005). Neurology 98(18_Supplement):3068CrossRef
go back to reference McGarry A, Rosanbalm S, Leinonen M et al (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23:37–45CrossRefPubMed McGarry A, Rosanbalm S, Leinonen M et al (2024) Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 23:37–45CrossRefPubMed
go back to reference Meissner WG, Remy P, Giordana C et al (2024) Trial of Lixisenatide in Early Parkinson’s Disease. N Engl J Med 390:1176–1185CrossRefPubMed Meissner WG, Remy P, Giordana C et al (2024) Trial of Lixisenatide in Early Parkinson’s Disease. N Engl J Med 390:1176–1185CrossRefPubMed
go back to reference Mucibabic M, Steneberg P, Lidh E et al (2020) α-Synuclein promotes IAPP fibril formation in vitro and β-cell amyloid formation in vivo in mice. Sci Rep 10:20438CrossRefPubMedPubMedCentral Mucibabic M, Steneberg P, Lidh E et al (2020) α-Synuclein promotes IAPP fibril formation in vitro and β-cell amyloid formation in vivo in mice. Sci Rep 10:20438CrossRefPubMedPubMedCentral
go back to reference Novak P, Pimentel Maldonado DA, Novak V (2019) Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. PLoS ONE 14:e0214364CrossRefPubMedPubMedCentral Novak P, Pimentel Maldonado DA, Novak V (2019) Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study. PLoS ONE 14:e0214364CrossRefPubMedPubMedCentral
go back to reference Ogaki K, Fujita H, Nozawa N et al (2023) Impact of diabetes and glycated hemoglobin level on the clinical manifestations of Parkinson’s disease. J Neurol Sci 454:120851CrossRefPubMed Ogaki K, Fujita H, Nozawa N et al (2023) Impact of diabetes and glycated hemoglobin level on the clinical manifestations of Parkinson’s disease. J Neurol Sci 454:120851CrossRefPubMed
go back to reference Ou R, Wei Q, Hou Y et al (2021) Effect of diabetes control status on the progression of Parkinson’s disease: A prospective study. Ann Clin Transl Neurol 8:887–897CrossRefPubMedPubMedCentral Ou R, Wei Q, Hou Y et al (2021) Effect of diabetes control status on the progression of Parkinson’s disease: A prospective study. Ann Clin Transl Neurol 8:887–897CrossRefPubMedPubMedCentral
go back to reference Pagano G, Polychronis S, Wilson H et al (2018) Diabetes mellitus and Parkinson disease. Neurology 90:e1654–e1662CrossRefPubMed Pagano G, Polychronis S, Wilson H et al (2018) Diabetes mellitus and Parkinson disease. Neurology 90:e1654–e1662CrossRefPubMed
go back to reference Pang Y, Lin S, Wright C et al (2016) Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. Neuroscience 318:157–165CrossRefPubMed Pang Y, Lin S, Wright C et al (2016) Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats. Neuroscience 318:157–165CrossRefPubMed
go back to reference Pezzoli G, Cereda E, Amami P et al (2023) Onset and mortality of Parkinson’s disease in relation to type II diabetes. J Neurol 270:1564–1572CrossRefPubMed Pezzoli G, Cereda E, Amami P et al (2023) Onset and mortality of Parkinson’s disease in relation to type II diabetes. J Neurol 270:1564–1572CrossRefPubMed
go back to reference Rhee SY, Han K-D, Kwon H et al (2020) Association Between Glycemic Status and the Risk of Parkinson Disease: a Nationwide Population-Based Study. Diabetes Care 43:2169–2175CrossRefPubMedPubMedCentral Rhee SY, Han K-D, Kwon H et al (2020) Association Between Glycemic Status and the Risk of Parkinson Disease: a Nationwide Population-Based Study. Diabetes Care 43:2169–2175CrossRefPubMedPubMedCentral
go back to reference Simon KC, Chen H, Schwarzschild M, Ascherio A (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69:1688–1695CrossRefPubMed Simon KC, Chen H, Schwarzschild M, Ascherio A (2007) Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology 69:1688–1695CrossRefPubMed
go back to reference Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333–1346CrossRefPubMed Stumvoll M, Goldstein BJ, van Haeften TW (2005) Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365:1333–1346CrossRefPubMed
go back to reference Svenningsson P, Wirdefeldt K, Yin L et al (2016) Reduced incidence of Parkinson’s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. Mov Disord 31:1422–1423CrossRefPubMed Svenningsson P, Wirdefeldt K, Yin L et al (2016) Reduced incidence of Parkinson’s disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study. Mov Disord 31:1422–1423CrossRefPubMed
go back to reference Uyar M, Lezius S, Buhmann C et al (2022) Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson’s Disease (MARK-PD Study). Mov Disord 37:1299–1304CrossRefPubMed Uyar M, Lezius S, Buhmann C et al (2022) Diabetes, Glycated Hemoglobin (HbA1c), and Neuroaxonal Damage in Parkinson’s Disease (MARK-PD Study). Mov Disord 37:1299–1304CrossRefPubMed
go back to reference Veith Sanches L, Greten S, Doll-Lee J et al (2024) SEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study. Neuropsychiatr Dis Treat 20:1849–1859CrossRefPubMedPubMedCentral Veith Sanches L, Greten S, Doll-Lee J et al (2024) SEND-PD in Parkinsonian Syndromes: Results of a Monocentric Cross-Sectional Study. Neuropsychiatr Dis Treat 20:1849–1859CrossRefPubMedPubMedCentral
go back to reference Wang M, Tian T, Zhou H et al (2024) Metformin normalizes mitochondrial function to delay astrocyte senescence in a mouse model of Parkinson’s disease through Mfn2-cGAS signaling. J Neuroinflammation 21:81CrossRefPubMedPubMedCentral Wang M, Tian T, Zhou H et al (2024) Metformin normalizes mitochondrial function to delay astrocyte senescence in a mouse model of Parkinson’s disease through Mfn2-cGAS signaling. J Neuroinflammation 21:81CrossRefPubMedPubMedCentral
go back to reference Yang Y-W, Hsieh T-F, Li C-I et al (2017) Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore) 96:e5921CrossRefPubMed Yang Y-W, Hsieh T-F, Li C-I et al (2017) Increased risk of Parkinson disease with diabetes mellitus in a population-based study. Medicine (Baltimore) 96:e5921CrossRefPubMed
Metadata
Title
Impact of diabetes mellitus type two on incidence and progression of Parkinson’s disease: a systematic review of longitudinal patient cohorts
Authors
Olga Stockmann
Lan Ye
Stephan Greten
David Chemodanow
Florian Wegner
Martin Klietz
Publication date
23-01-2025
Publisher
Springer Vienna
Published in
Journal of Neural Transmission
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-025-02882-7

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Advances in Alzheimer's

Alzheimer's research and care is changing rapidly. Keep up with the latest developments from key international conferences, together with expert insights on how to integrate these advances into practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Healthcare IME
Learn more